CAPDRIVE
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

CAPDRIVE Trademark

Serial Number: 79370455 • Registration: 7561433

CAPDRIVE is a trademark filed by Skyline Therapeutics (Shanghai) Co.,Ltd. on March 2, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Skyline Therapeutics (Shanghai) Co.,Ltd.

Room 1, Floor 2, Building C,

Entity Type: 99

Trademark Details

Filing Date

March 2, 2023

Registration Date

November 12, 2024

Published for Opposition

August 27, 2024

Goods & Services

Stem cells for medical purposes; biochemical medicine for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; biological preparations for medical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; biological tissue cultures for medical purposes; chemical preparations for medical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; chemical preparations for pharmaceutical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; chemico-pharmaceutical preparations for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the central nervous system; ophthalmological preparations; pharmaceutical preparations for the treatment of immune system related diseases and disorders; cardiovascular agents for medical purposes; cellular function activating agents for medical purposes; pharmaceutical products for the prevention and treatment of cancer

Scientific research and development; scientific research; technological research, namely, research on the subject of pharmaceuticals; biological research; scientific research in the nature of conducting clinical trials for others; medical research; pharmaceutical research services; research on the subject of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; structural and functional analysis of genomes; biotechnology research; analysis of the mode of action of chemical combinations on animals; research and development services in the field of antibodies; genetic testing for scientific research purposes; biological research and analysis; pharmaceutical drug development services; DNA screening for scientific research purposes; medical research; testing of pharmaceuticals; biomedical research services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 3, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 11, 2025 FICS
FINAL DISPOSITION PROCESSED
Apr 11, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 12, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 12, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 12, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 9, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 23, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 23, 2024 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 27, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 27, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 7, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 22, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 19, 2024 TROA
REFUSAL PROCESSED BY IB
Feb 14, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 19, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jan 19, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 2, 2023 RFCR
NON-FINAL ACTION WRITTEN
Dec 1, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 1, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
May 30, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 26, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 25, 2023 REPR